Trial Profile

A Phase 1b Study to Investigate the Safety, Efficacy and Pharmacodynamics of Cerdulatinib for the Treatment of Atopic Dermatitis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Dec 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cerdulatinib (Primary)
Indications Atopic dermatitis
Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Proof of concept; Therapeutic Use

Most Recent Events

21 Dec 2018 New trial record
10 Dec 2018 Results published in the Experimental Dermatology Journal: 3rd Inflammatory Skin Disease Summit-The Translational Revolution.
06 Dec 2018 According to a Dermavant Sciences media release, data from this trial will be presented at the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place (12-15th Dec, 2018, Vienna, Austria).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com